Plain-English translation of NCT07355218 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 3 clinical trial testing a medication called for people with active skin manifestations of lupus. The study will compare to a placebo (a pill with no active ingredient) over 24 weeks to see if the medication helps reduce skin symptoms and is safe to use. About 202 people worldwide will participate.
Lupus skin disease can be difficult to treat and significantly affect quality of life. Researchers believe this medication may offer a new treatment option for people whose skin symptoms aren't adequately controlled with current standard care.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic approximately every 4 weeks for 24 weeks of treatment, with one brief video visit at week 2. You'll take either the study medication or a placebo pill by mouth each day. At each visit, the study team will check your skin symptoms, ask how you're feeling, and monitor your health through blood tests and other assessments. The entire study will last up to 35 weeks from enrollment through final follow-up.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States